Table 2

Selection of source and study populations
Inclusion/exclusion criteria n (%)
Source Population
 GHP members aged ≥18 years who received myelosuppressive chemotherapy from 01/01/04 - 4/30/10 3823 (100.0)
  plus continuous health benefits during 60-day pretreatment period 3660 (95.7)
  plus ≥2 claims with primary cancer diagnosis beginning 60 days prior to chemotherapy initiation 3193 (83.5)
Study Population
  plus admission to acute care, short stay hospital during chemotherapy course 772 (20.2)
  plus admitted to hospital within GHS 373 (9.8)
  plus ANC data available within 1 day of hospital admission 357 (9.3)

GHP: Geisinger Health Plan; GHS: Geisinger Health System; ANC: absolute neutrophil count.

Weycker et al.

Weycker et al. BMC Health Services Research 2013 13:60   doi:10.1186/1472-6963-13-60

Open Data